Navigation Links
Cephalon Reports Another Strong Quarter
Date:10/28/2008

s of our business, sales, earnings and cash flow in light of current general economic conditions; sales, SG&A, R&D, adjusted net income and basic adjusted income per common share guidance for full-year 2008 and full- year 2009; and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward- looking statements. Furthermore, Cephalon does not intend to update publicly any forward-looking statement, except as required by law. The Private Securities Litigation Reform Act of 1995 permits this discussion.

This press release and/or the financial results attached to this press release include "Adjusted Net Income," "Basic Adjusted Income per Common Share," "Adjusted Net Income Guidance," "Basic Adjusted Income per Common Share Guidance," and "Diluted Adjusted Income Per Common Share," amounts that are considered "non-GAAP financial measures" under SEC rules. As required, we have provided reconciliations of these measures. Additional required information is located in the Form 8-K furnished to the SEC in connection with this press release.

CEPHALON, INC. AND SUBSIDIARIES

CONSO
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... July 01, 2015 , ... The next-generation sequencing (NGS) clinical market is poised ... molecular diagnostics industry. BCC Research reveals in its new report that the market drivers ... and a growing need for better diagnostics as part of a molecular diagnostics trend. ...
(Date:7/1/2015)... ... ... A newly launched business plan contest will ask startup companies from around the ... R&D. The Pistoia Alliance President’s Startup Challenge 2015 will see small and medium enterprises ... mentorship from a senior industry figure drawn from the Pistoia Alliance membership. , The ...
(Date:6/30/2015)... R-Japan Co.,Ltd. obtained the license of cell processing facility under ... Ministry of Health, Labour and Welfare Kinki Bureau of Health ... fact that R- Japan received the license ... Medical Devices Agency (PMDA) on May 18, 2015 two months ... manufacturing service to medical institutions. As of November 25, 2014, ...
(Date:6/30/2015)... -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP ), a specialty ... unmet medical needs in women,s health, today announced ... at the Cantor Fitzgerald Inaugural Healthcare Conference as ... PM EDTLocation: , Le Parker Meridien Hotel, New ... under  ,Investor, or  click here The ...
Breaking Biology Technology:NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3R-Japan Obtained Autologous Stem Cell Manufacturing License from the Ministry of Health, Labour and Welfare 2Juniper Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015 2
... LA JOLLA, Calif. , May 13 ... company focused on developing topically administered products using its proprietary ... ended March 31, 2010 .  The Company also highlighted ... , ...
... May 13 Repligen Corporation (Nasdaq: RGEN ) ... Application (IND) with the Food and Drug Administration (FDA) for ... 3 (HDAC-3) inhibitor.  This is a double-blind, single ascending dose, ... and safety profile of RG2833 in up to 40 subjects. ...
... , ... of Cobalis Corp announced the appointment of Martin Marion as Chief Executive Officer. ... Irvine, CA (PRWEB) May ... appointment of Martin Marion as Chief Executive Officer. Mr. Marion is a seasoned strategic ...
Cached Biology Technology:Transdel Pharmaceuticals Reports First Quarter 2010 Results 2Transdel Pharmaceuticals Reports First Quarter 2010 Results 3Transdel Pharmaceuticals Reports First Quarter 2010 Results 4Transdel Pharmaceuticals Reports First Quarter 2010 Results 5Repligen Files Investigational New Drug Application with FDA for First Drug Targeting the Core Genetic Defect of Friedreich's Ataxia 2Repligen Files Investigational New Drug Application with FDA for First Drug Targeting the Core Genetic Defect of Friedreich's Ataxia 3Repligen Files Investigational New Drug Application with FDA for First Drug Targeting the Core Genetic Defect of Friedreich's Ataxia 4Cobalis Corp. Appoints Martin Marion as Chief Executive Officer 2Cobalis Corp. Appoints Martin Marion as Chief Executive Officer 3
(Date:6/10/2015)... , June 10, 2015 ... Sensor Market by Technology (Ultrasound, TOF, Structured Light, ... Electronics, Entertainment, Automotive) and by Geography - Trends ... MarketsandMarkets, the market is expected to reach $3,319.71 ... 25.51% between 2015 and 2020. Browse ...
(Date:6/9/2015)... DUBLIN , June 09, 2015 ... the addition of the "Gesture Recognition & ... Application (Consumer Electronics, Automotive, & Others), Product (Biometric ... Forecast to 2020" report to their offering. ... sensing market is expected to reach $ 23.55 ...
(Date:6/8/2015)... June 8, 2015  The Secure Identity ... selection of Troy Potter of L-3 ... SIBA is a non-profit association that was established ... education and implementation of solutions that protect and ... ...
Breaking Biology News(10 mins):3D Sensor Market Worth $3,319.71 Million by 2020 23D Sensor Market Worth $3,319.71 Million by 2020 33D Sensor Market Worth $3,319.71 Million by 2020 4Global Gesture Recognition & Touchless Sensing (Technology, Application & Products) Market 2015-2020 2Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 2Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 3Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 4Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 5
... from the National Human Genome Research Institute (NHGRI), part ... that mammalian chromosomes have evolved by breaking at specific ... many of the breakage hotspots are also involved in ... July 22 issue of the journal Science, a team ...
... of Southern California and the Doheny Eye Institute's Doheny ... six patients implanted with an intraocular retinal prosthesis-more popularly ... partnership with Second Sight Medical Products, Inc., of Sylmar, ... at the Keck School of Medicine and the lead ...
... the Department of Biological Sciences have unraveled the details ... Specific DNA sequences that appear to have persisted in ... not be simply lying dormant. Instead, the researchers say ... human evolution by surreptitiously spawning hyperactive progeny copies, giving ...
Cached Biology News:Multi-species genome comparison sheds new light on evolutionary processes, cancer mutations 2Multi-species genome comparison sheds new light on evolutionary processes, cancer mutations 3Six previously blind patients detect light, motion, identify objects with retinal prostheses 2Scientists track stealth DNA elements in primate evolution 2Scientists track stealth DNA elements in primate evolution 3
...
Anti-G-alpha-i 1 G-Protein Host: mouse monoclonal Species Reactivity: human, mouse, rat Applications: WB Storage: 4C...
oligophrenin-1 (H-100)...
Mouse monoclonal [DAPK-55] to DAP Kinase 1 ( Abpromise for all tested applications). entrezGeneID: 1612 SwissProtID: P53355...
Biology Products: